Categories: News

NextGen Healthcare Announces Retirement of Chief Medical Officer Betty Rabinowitz and Promotion of Robert Murry to Chief Medical Officer

ATLANTA–(BUSINESS WIRE)–$NXGN #NextGenHealthcare–NextGen Healthcare, Inc. (Nasdaq: NXGN), a leading provider of ambulatory-focused technology solutions, today announced the retirement of its chief medical officer, Betty Rabinowitz, MD, FACP, effective December 31, 2021. Dr. Rabinowitz joined the company in 2017, following her role as one of the founders and former CEO of EagleDream Health, the cloud-based analytics and population management solution acquired by NextGen Healthcare. “Dr. Betty” as she is known in the industry, was appointed to the newly created chief medical officer role in 2018. Her lengthy healthcare career spans over 40 years and includes extensive clinical and academic experience.


The company also announced that, following an external and internal search, its chief medical Informatics officer (CMIO), Robert (Bob) Murry, Ph.D., M.D., FAAFP, has been promoted to chief medical officer. Dr. Murry has been with NextGen Healthcare since 2012 and has guided the company’s strategy and vision for select products and services. Under his leadership, the company’s NextGen® Enterprise solution has risen to become the top-rated ‘Best in KLAS’ ambulatory electronic health record system (11-75 physicians) in 2021. Previously, Dr. Murry served as Medical Director for Ambulatory Informatics and CMIO for Hunterdon Medical Center while practicing family medicine at Delaware Valley Health Center.

“On behalf of the entire NextGen Healthcare team, I would like to thank Dr. Betty for her invaluable contributions to our company and the healthcare industry throughout her career, particularly as a pioneer of population health solutions for ambulatory providers,” said David Sides, president and chief executive officer for NextGen Healthcare. ”She has played a pivotal role in NextGen Healthcare’s growth. We are grateful for her friendship, vision and commitment to better healthcare for all. We wish her the very best in retirement.”

Sides continued, “I would also like to congratulate Dr. Bob on his promotion to chief medical officer – a role which he is extremely well suited for given his wealth of clinical experience, technical knowledge and long-term, trusted relationship with our clients. I am confident he will flourish as CMO and he will build on the outstanding foundation established by Dr. Betty.”

About NextGen Healthcare, Inc.

NextGen Healthcare, Inc. (Nasdaq: NXGN) is a leading provider of ambulatory-focused technology solutions. We are empowering the transformation of ambulatory care—partnering with medical, behavioral and dental providers in their journey to value-based care to make healthcare better for everyone. We go beyond EHR and PM. Our integrated solutions help increase clinical productivity, enrich the patient experience, and ensure healthy financial outcomes. We believe in better. Learn more at nextgen.com, and follow us on Facebook, Twitter, LinkedIn, YouTube and Instagram.

Contacts

Media Contact

Tami Stegmaier

(949) 237-6083

tstegmaier@nextgen.com

Investor Relations Contact

Matthew Scalo

(415) 370-9202

mscalo@nextgen.com

Staff

Recent Posts

Vivos Inc.’s IsoPet® Division Achieves Exceptional Growth in 2024, Expanding Certified Veterinary Clinics Nationwide

Richland, WA, Dec. 26, 2024 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) is pleased to…

3 hours ago

Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B

– ABI-4334 was well-tolerated with a favorable safety profile and half-life supporting once-daily oral dosing…

3 hours ago

Optinose Announces 1-for-15 Reverse Stock Split

YARDLEY, Pa., Dec. 26, 2024 (GLOBE NEWSWIRE) -- Optinose, Inc. (NASDAQ: OPTN), a pharmaceutical company…

3 hours ago

TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium

WALTHAM, Mass., Dec. 26, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage…

3 hours ago

Clearmind Medicine Looks to Move Forward with its Novel Psychedelic MEAI- Based Alcohol Substitute

Company recently signed a non-binding term sheet with Dr Glitter Pty Ltd for mutual development…

3 hours ago

SciSparc: AutoMax Announces $13 Million First Delivery of JAC Vehicles Following Regulatory Approval for Direct Importation

TEL AVIV, Israel, Dec. 26, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or…

3 hours ago